COMMUNIQUÉS West-GlobeNewswire
-
Microbot Medical® Enters Into an Agreement to Expand Access for America’s Veteran and Military Patient Populations
16/06/2026 -
Le King Faisal Specialist Hospital présente la chirurgie robotique comme modèle de soins spécialisés axés sur l’innovation lors du congrès HLTH Europe 2026
16/06/2026 -
Propanc Biopharma’s CEO Tours European CDMO & Plans for GMP Production of PRP for Phase 1b, FIH Study
16/06/2026 -
Erdem Hospital Highlights Emotional Wellbeing as Part of Patient Care with London Wellness Event
16/06/2026 -
Picard Medical and SynCardia to Present New In Vivo Emperor Total Artificial Heart Data and Patient Outcome Research at ASAIO 2026
16/06/2026 -
Quoin Pharmaceuticals Announces Positive Clinical Update from Ongoing Pediatric Netherton Syndrome Compassionate Use Program
16/06/2026 -
BioAge Labs Announces First Participant Dosed in QUELL-CV, a Phase 2 Proof-of-Concept Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Patients at Elevated Cardiovascular Risk
16/06/2026 -
Breckenridge Distillery Celebrates America's 250th Anniversary with the Launch of Patriotic Reserve Bourbon Whiskey
16/06/2026 -
Through the MUHC Foundation, one family helps fuel breakthrough in rare cancer research
16/06/2026 -
Wolverine Peptide Stack & Blend Introduced by Koi Peptides for Laboratory Research
16/06/2026 -
MultiValent Biotherapies Launches with $27 Million Series A Financing to Advance Development of Targeted Prostate Cancer Drug Conjugate
16/06/2026 -
Creative Medical Technology Holdings, Inc. Advances Project PHOENIX into Nationwide AI Driven Virtual Data Collection Phase for U.S. Veterans Exposed to Burn Pits and Toxic Hazards
16/06/2026 -
Optimi Health Launches Standardized Microdose Psilocybin Products for Clinical Research
16/06/2026 -
King Faisal Specialist Hospital Presents Robotic Surgery as a Model for Innovation-Driven Specialized Care at HLTH Europe 2026
16/06/2026 -
Cingulate Issued First U.S. Patent for Lead ADHD Asset CTx-1301
16/06/2026 -
Entera Reports Robust Preclinical Data for EB612 (Oral LA-PTH(1-34)) for Hypoparathyroidism and EB618 (Oral GLP-1/Glucagon) for Obesity at ENDO 2026
16/06/2026 -
Adial Pharmaceuticals Expands Executive Leadership Team and Closes PIPE Financing
16/06/2026 -
Trinity Biotech Awarded Significant Orders for Over 2 Million TrinScreen HIV Tests And Reports Q1 2026 Financial Results
16/06/2026 -
Nexalin Technology Announces Two Clinical Abstracts Accepted for Presentation at the 2026 NYC Neuromodulation Conference Highlighting Preliminary Clinical Results Across Anxiety, Depression, Insomnia and Quality of Life
16/06/2026
Pages